Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Parikh

Showing results (331-340 of 385) with videos related to

Pageof 39
Sort By:
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|November 11, 2020
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif MajeurJennifer Swainson, Alexander McGirr, Pierre Blier, et al.
Molecular Psychiatry|October 14, 2015
Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trialL N Yatham, S Beaulieu, A Schaffer, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|November 18, 2025
The Canadian Network for Mood and Anxiety Treatments Task Force Recommendations for the Use of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplants in Adults With Major Depressive Disorder: Recommandations du Groupe de travail du Réseau canadien pour le traitement des troubles de l'humeur et de l'anxiété (Canadian Network for Mood and Anxiety Treatments, CANMAT) concernant l'utilisation des probiotiques, des prébiotiques, des symbiotiques et de la transplantation de microbiote fécal chez les adultes atteints de trouble dépressif majeurAnees Bahji, Elisa Brietzke, Noah C A Cooke, et al.
American Journal of Nephrology|November 21, 2022
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor DanicopanSteven D Podos, Howard Trachtman, Gerald B Appel, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|July 24, 2025
Standardized EEG for multi-site biomarker-informed trials: Implementation in the Canadian Biomarker Integration Network in DepressionBenjamin Schwartzmann, Prabhjot Dhami, Raaj Chatterjee, et al.
Journal of Affective Disorders|November 24, 2017
The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot studyAnusha Baskaran, Faranak Farzan, Roumen Milev, et al.
Translational Psychiatry|September 6, 2022
Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 studyFarhana Islam, Victoria S Marshe, Leen Magarbeh, et al.
The Journal of Clinical Psychiatry|May 16, 2019
Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant TreatmentRaoul Belzeaux, Laura M Fiori, Juan Pablo Lopez, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|August 17, 2022
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive DisorderJoshua D Rosenblat, M Ishrat Husain, Yena Lee, et al.
American Heart Journal|October 19, 2025
Worsening heart failure events in adults with mild-to-moderate chronic kidney diseaseLinda Ye, Michael P Girouard, Alan S Go, et al.
Pageof 39

Showing results (331-340 of 385) with videos related to

Sort By:
Pageof 39
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|November 11, 2020
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif MajeurJennifer Swainson, Alexander McGirr, Pierre Blier, et al.
Molecular Psychiatry|October 14, 2015
Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trialL N Yatham, S Beaulieu, A Schaffer, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|November 18, 2025
The Canadian Network for Mood and Anxiety Treatments Task Force Recommendations for the Use of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplants in Adults With Major Depressive Disorder: Recommandations du Groupe de travail du Réseau canadien pour le traitement des troubles de l'humeur et de l'anxiété (Canadian Network for Mood and Anxiety Treatments, CANMAT) concernant l'utilisation des probiotiques, des prébiotiques, des symbiotiques et de la transplantation de microbiote fécal chez les adultes atteints de trouble dépressif majeurAnees Bahji, Elisa Brietzke, Noah C A Cooke, et al.
American Journal of Nephrology|November 21, 2022
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor DanicopanSteven D Podos, Howard Trachtman, Gerald B Appel, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|July 24, 2025
Standardized EEG for multi-site biomarker-informed trials: Implementation in the Canadian Biomarker Integration Network in DepressionBenjamin Schwartzmann, Prabhjot Dhami, Raaj Chatterjee, et al.
Journal of Affective Disorders|November 24, 2017
The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot studyAnusha Baskaran, Faranak Farzan, Roumen Milev, et al.
Translational Psychiatry|September 6, 2022
Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 studyFarhana Islam, Victoria S Marshe, Leen Magarbeh, et al.
The Journal of Clinical Psychiatry|May 16, 2019
Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant TreatmentRaoul Belzeaux, Laura M Fiori, Juan Pablo Lopez, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|August 17, 2022
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive DisorderJoshua D Rosenblat, M Ishrat Husain, Yena Lee, et al.
American Heart Journal|October 19, 2025
Worsening heart failure events in adults with mild-to-moderate chronic kidney diseaseLinda Ye, Michael P Girouard, Alan S Go, et al.
Pageof 39